Williams Targeting Biofilms in Translational Research, Device Development, and Industrial Sectors

1. Auflage 2019
ISBN: 978-3-030-30667-0
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 162 Seiten, eBook

This book offers a much-needed discussion on the targeting of biofilm-related infections. Chapters include discussions on the impact of biofilm on medical implants, industrial applications, as well as wound and tissue infections. It also offers discussions on regulatory management for industrial sectors and medical environments. Given that there continues to be a paucity of effective antimicrobial products, devices, and coatings in clinical and industrial use that effectively reduce rates of infection or biofilm-related problems,
Targeting Biofilms in Translational Research, Device Development, and Industrial Sectors
, offers a fresh and much-needed perspective aimed at helping create healthier controlled environments and safer devices.  

This comprehensive book is indispensable for industrial and academic translational researchers, device developers, and regulatory experts looking to create more effective antimicrobial products.

Zielgruppe

Research

Autoren/Hrsg.

Williams, Dustin L.

Inhaltsverzeichnis

Overview and data in biofilm sectors: why targeting biofilms is necessary, Dustin Williams

Impact of biofilms in orthopaedics as they relate to regulatory requirements and needs to be met, David Armbruster, MS, MSE, R&D Group Manager, DePuy Synthes

Clinical problems of biofilm implant-related infection and methods/need to target biofilms in patients, Javad Parvizi, MD, Professor of Orthopaedic Surgery, Rothman Institute at Thomas Jefferson University Hospital

Impact of biofilms in catheter systems and regulatory considerations,

Bryan Haymond, MBA, Product Manager, Bard Access Systems

Potential benefits of targeting biofilms in wound-related and other tissue infections, Garth James, PhD, Associate Research Professor, Center for Biofilm Engineering, Montana State University

Biofilms, prevalence and problems related to injured soldiers and military healthcare facilities, COL Clinton K. Murray, MD, FACP, FIDSA, Colonel, US Army

FDA insight into the biofilm problem and regulatory management strategy for medical devices, K. Scott Phillips, PhD, Biofilms Research Group Leader, The US FDA and CDR US Public Health Service

Benefits of standardizing approaches to assessing antimicrobial efficacies against biofilms for industrial applications, Darla Goeres, PhD, Associate Research Professor, Chemical & Biological Engineering, Standards Biofilm Methods Laboratory, Center for Biofilm Engineering, Montana State University

EPA insight in the biofilm problem and regulatory management strategy for industrial sectors, Steve Tomasino, PhD, Senior Scientist, Environmental Protection Agency

Über Autor(innen)

Dustin L. Williams has developed translational animal models of biofilm-related infection to mimic clinical scenarios, such as open fractures, wherein biofilms from natural sources (e.g. soil) may be initial contaminants of a wound site. He is a founding member of three companies that have been launched out of the University of Utah; each focusing on anti-biofilm technologies. In 2016, he became the Director of the Bone and Joint Research Lab located in the Department of Veterans Affairs in Salt Lake City, UT. Dustin and his team manage research programs that span biofilm-related infections, osseointegration, bone pathologies such as heterotopic ossification, and specialize in hard plastic embedment for histological analysis.